Literature DB >> 16480864

4-Amino derivatives of the Hsp90 inhibitor CCT018159.

Xavier Barril1, Mandy C Beswick, Adam Collier, Martin J Drysdale, Brian W Dymock, Alexandra Fink, Kate Grant, Robert Howes, Allan M Jordan, Andrew Massey, Allan Surgenor, Joanne Wayne, Paul Workman, Lisa Wright.   

Abstract

Novel piperazinyl, morpholino and piperidyl derivatives of the pyrazole-based Hsp90 inhibitor CCT018159 are described. Structure-activity relationships have been elucidated by X-ray co-crystal analysis of the new compounds bound to the N-terminal domain of human Hsp90. Key features of the binding mode are essentially identical to the recently reported potent analogue VER-49009. The most potent of the new compounds has a methylsulfonylbenzyl substituent appended to the piperazine nitrogen, possesses an IC50 of less than 600 nM binding against the enzyme and demonstrates low micromolar inhibition of tumour cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16480864     DOI: 10.1016/j.bmcl.2006.01.099

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  12 in total

1.  High-throughput assay for the identification of Hsp90 inhibitors based on Hsp90-dependent refolding of firefly luciferase.

Authors:  Lakshmi Galam; M Kyle Hadden; Zeqiang Ma; Qi-Zhuang Ye; Bo-Geon Yun; Brian S J Blagg; Robert L Matts
Journal:  Bioorg Med Chem       Date:  2007-01-04       Impact factor: 3.641

2.  A combined molecular modeling study on a series of pyrazole/isoxazole based human Hsp90α inhibitors.

Authors:  Ying Yang; Huanxiang Liu; Juan Du; Jin Qin; Xiaojun Yao
Journal:  J Mol Model       Date:  2011-03-04       Impact factor: 1.810

3.  Application of docking-based comparative intermolecular contacts analysis to validate Hsp90α docking studies and subsequent in silico screening for inhibitors.

Authors:  Mahmoud A Al-Sha'er; Mutasem O Taha
Journal:  J Mol Model       Date:  2012-06-16       Impact factor: 1.810

4.  Inhibition of gastric tumor growth by a novel Hsp90 inhibitor.

Authors:  Chunwan Lu; Di Liu; Jing Jin; Hemantkumar Deokar; Yi Zhang; John K Buolamwini; Xiaoming Yu; Chunhong Yan; Xiaoguang Chen
Journal:  Biochem Pharmacol       Date:  2013-02-13       Impact factor: 5.858

Review 5.  Design, synthesis, and evaluation of small molecule Hsp90 probes.

Authors:  Tony Taldone; Danuta Zatorska; Pallav D Patel; Hongliang Zong; Anna Rodina; James H Ahn; Kamalika Moulick; Monica L Guzman; Gabriela Chiosis
Journal:  Bioorg Med Chem       Date:  2011-03-12       Impact factor: 3.641

6.  Discovery of aminoquinolines as a new class of potent inhibitors of heat shock protein 90 (Hsp90): Synthesis, biology, and molecular modeling.

Authors:  Thota Ganesh; Jaeki Min; Pahk Thepchatri; Yuhong Du; Lian Li; Iestyn Lewis; Larry Wilson; Haian Fu; Gabriela Chiosis; Raymond Dingledine; Dennis Liotta; James P Snyder; Aiming Sun
Journal:  Bioorg Med Chem       Date:  2008-05-27       Impact factor: 3.641

Review 7.  Discovery and development of heat shock protein 90 inhibitors.

Authors:  Tony Taldone; Weilin Sun; Gabriela Chiosis
Journal:  Bioorg Med Chem       Date:  2008-11-06       Impact factor: 3.641

8.  Different poses for ligand and chaperone in inhibitor-bound Hsp90 and GRP94: implications for paralog-specific drug design.

Authors:  Robert M Immormino; Louis E Metzger; Patrick N Reardon; D Eric Dollins; Brian S J Blagg; Daniel T Gewirth
Journal:  J Mol Biol       Date:  2009-04-08       Impact factor: 5.469

9.  Thermodynamics of aryl-dihydroxyphenyl-thiadiazole binding to human Hsp90.

Authors:  Egidijus Kazlauskas; Vilma Petrikaitė; Vilma Michailovienė; Jurgita Revuckienė; Jurgita Matulienė; Leonas Grinius; Daumantas Matulis
Journal:  PLoS One       Date:  2012-05-24       Impact factor: 3.240

10.  Modeling signal propagation mechanisms and ligand-based conformational dynamics of the Hsp90 molecular chaperone full-length dimer.

Authors:  Giulia Morra; Gennady Verkhivker; Giorgio Colombo
Journal:  PLoS Comput Biol       Date:  2009-03-20       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.